Masatoshi Mutazono, Ph.D.
Team Leader ARCALIS
Seminars
Thursday 3rd December 2026
Integrated mRNA-LNP Technologies and Manufacturing Platforms Supporting Personalized Cancer Vaccine Development
12:00 pm
- ARCALIS's integrated mRNA/LNP platform combines sequence optimization, high-throughput screening, analytical characterization, and GMP-compliant manufacturing in a single workflow
- HARNA™ codon optimization, self-amplifying RNA (saRNA), and organ-selective LNP formulations deliver enhanced and sustained protein expression with optimized organ-selective delivery
- Seamless connection from discovery to GMP drug substance and drug product manufacturing enables efficient scale-up and accelerates personalized cancer vaccine development.
